First-Time-Right CMC Submissions in an AI Era: Closing the Guidance Gap for Emerging and Small Pharma

AI can accelerate the work. Expert review, scientific rationale, and submission discipline make it reviewer-ready.

Introduction

For emerging and small pharmaceutical companies, the pressure to deliver high-quality Chemistry, Manufacturing, and Controls (CMC) submissions has never been greater. Lean teams, compressed timelines, evolving regulatory expectations, and increasingly complex product portfolios create a challenging environment where even minor inconsistencies can lead to costly delays.

Unlike large organizations with dedicated regulatory operations, quality, and submission excellence teams, smaller organizations often operate with limited resources. As a result, they face a significant guidance gap: the need to produce reviewer-ready submissions with the same level of rigor and consistency expected from larger enterprises, but with fewer people, systems, and institutional knowledge.

The rise of Artificial Intelligence (AI) presents a compelling opportunity to bridge this gap. However, AI alone is not the answer. Achieving First-Time-Right (FTR) CMC submissions requires the right blend of technology, expert review, quality control discipline, and regulatory know-how.

The Challenge: Small Teams, Big Expectations

Regulatory authorities expect every CMC submission to present a clear, scientifically justified story supported by accurate and traceable data. Whether the submission is for a clinical trial application, marketing authorization, post-approval change, or lifecycle management activity, reviewers expect:

• Data consistency across all sections
• Complete traceability to source information
• Well-documented quality controls
• Clear scientific rationale for decisions
• Compliance with evolving regulatory standards

For small and mid-sized companies, meeting these expectations can be particularly challenging.

Often, information exists across multiple spreadsheets, reports, manufacturing records, and vendor-generated documents. Subject matter experts may be balancing multiple responsibilities, and institutional knowledge can reside with only a few individuals. In such environments, maintaining consistency across an entire submission package becomes increasingly difficult.

The result is a heightened risk of:

• Data discrepancies
• Incomplete documentation
• Inconsistent terminology
• Weak scientific justifications
• Increased regulatory questions and review cycles

These issues not only impact submission quality but can also affect critical development and commercialization timelines.

Why First-Time-Right Matters More Than Ever

Every round of regulatory questions creates additional effort for already stretched teams. Responding to deficiencies often requires cross-functional coordination, document updates, data verification, and management oversight.

A First Time-Right approach focuses on identifying and resolving issues before they reach regulatory reviewers.

Organizations that achieve higher levels of submission quality can benefit from:

• Reduced rework and remediation efforts
• Faster review timelines
• Greater confidence during inspections and audits
• Improved operational efficiency
• Better utilization of internal resources

Most importantly, high-quality submissions support faster access to therapies for patients waiting for innovative treatments.

How AI Helps Bridge the Efficiency Gap

AI is rapidly becoming a valuable enabler for regulatory and CMC teams because it can automate many of the manual activities that consume significant time and resources.

1. Consistency Across Documentation

CMC submissions contain thousands of interconnected data points spanning specifications, manufacturing processes, analytical methods, stability results, and batch information.

AI-assisted review can help identify:

• Conflicting values across documents
• Inconsistent terminology
• Missing cross-references
• Potential gaps in supporting information

Rather than relying exclusively on manual review, teams can rapidly detect issues that may otherwise go unnoticed until regulatory review.

2. Improved Content Development

Preparing CMC narratives frequently requires consolidating information from technical reports, development documents, and manufacturing records.

AI can support teams by:

• Summarizing source content
• Highlighting relevant supporting information
• Standardizing language and structure
• Accelerating draft development

This enables subject matter experts to spend more time on scientific evaluation and less time on administrative compilation.

3. Better Knowledge Utilization

Smaller organizations often struggle to leverage prior submission experience because information is stored across multiple systems or documentation repositories.

AI-powered knowledge retrieval can help teams:

• Reuse previously approved content
• Apply established approaches consistently
• Reduce duplication of effort
• Capture organizational learning more effectively

For organizations with limited resources, this can substantially improve operational efficiency.

The Missing Piece: AI Is Not a Substitute for Submission Discipline

While AI offers powerful capabilities, regulatory submissions cannot rely solely on automation.

A common misconception is that AI-generated content automatically results in submission-ready documentation. In reality, the quality of a submission still depends on:

• Robust review processes
• Quality control checkpoints
• Scientific accuracy
• Regulatory expertise
• Cross-functional alignment

Regulatory reviewers are not evaluating whether a dossier was generated efficiently. They are evaluating whether the submission presents a complete, defensible, and scientifically sound rationale.

This is where human expertise remains essential.

The Importance of Reviewer-Ready Scientific Rationale

One of the most frequent causes of regulatory questions is not missing data, but insufficient explanation of the data.

Reviewers need to understand:

• Why a particular specification was selected
• How process parameters were justified
• Why analytical methods are appropriate
• How manufacturing changes were assessed
• What scientific rationale supports risk-based decisions

AI can help organize information and identify supporting evidence, but experienced CMC professionals are still required to transform technical data into a reviewer-ready scientific narrative.

The strongest submissions combine data with clear, persuasive scientific reasoning that anticipates reviewer expectations.

Where Celegence Creates Value

At Celegence, we believe the future of regulatory operations lies in combining AI-enabled efficiency with deep regulatory and quality expertise.

AI can help improve consistency, accelerate content development, and identify potential gaps. However, achieving true First-Time-Right performance requires a structured framework built around expert quality review and submission discipline.

Celegence helps organizations bridge the guidance gap by bringing together:

• AI-Assisted Consistency

Leveraging technology to identify inconsistencies, improve document harmonization, and support content readiness.

• Expert Quality Control

Applying experienced reviewer oversight to validate accuracy, completeness, and compliance.

• Submission Discipline

Implementing proven processes, governance models, and review methodologies that strengthen submission quality.

• Reviewer-Centric Thinking

Ensuring that documentation not only contains the right information but presents it in a way that supports efficient regulatory assessment.

This balanced approach allows organizations to benefit from innovation without compromising quality or regulatory confidence.

Looking Ahead

The future of CMC submissions will not be defined by AI alone. Success will belong to organizations that effectively combine advanced technologies with experienced regulatory professionals and disciplined quality processes.

For small and emerging pharmaceutical companies, AI offers an opportunity to close longstanding efficiency gaps. Yet technology delivers its greatest value when paired with expert oversight, strong traceability practices, rigorous QC review, and clear scientific storytelling.

First-Time-Right submissions are no longer an aspiration reserved for large pharmaceutical companies. With the right combination of tools, expertise, and process discipline, they are an achievable goal for organizations of any size.

Call to Action

Improve submission quality and consistency with a balanced approach that combines AI-assisted efficiencies, expert quality review, and proven submission discipline.

Celegence helps sponsors develop reviewer-ready CMC submissions that strengthen compliance, reduce rework, and support successful regulatory outcomes from the first submission onward. For lean and growing pharmaceutical teams, improving submission quality does not require choosing between technology and expertise.

Celegence combines AI-assisted workflows, experienced CMC professionals, quality review, and submission discipline to help sponsors develop consistent, scientifically sound, reviewer-ready CMC documentation.

Reduce rework. Strengthen submission readiness. Deliver with greater confidence.